ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While ORGO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ORGO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
In the past year ORGO had a positive cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
Of the past 5 years ORGO 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of ORGO (1.27%) is better than 94.02% of its industry peers.
With an excellent Return On Equity value of 2.10%, ORGO belongs to the best of the industry, outperforming 94.70% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.09%, ORGO belongs to the top of the industry, outperforming 94.36% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.45%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.27% | ||
| ROE | 2.1% | ||
| ROIC | 2.09% |
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 1.34%, ORGO belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
ORGO's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 2.91%, ORGO belongs to the best of the industry, outperforming 94.36% of the companies in the same industry.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a better Gross Margin (75.07%) than 85.81% of its industry peers.
In the last couple of years the Gross Margin of ORGO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.91% | ||
| PM (TTM) | 1.34% | ||
| GM | 75.07% |
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ORGO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ORGO has more shares outstanding
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.54 indicates that ORGO is not a great score, but indicates only limited risk for bankruptcy at the moment.
ORGO's Altman-Z score of 2.54 is fine compared to the rest of the industry. ORGO outperforms 73.50% of its industry peers.
The Debt to FCF ratio of ORGO is 9.92, which is on the high side as it means it would take ORGO, 9.92 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 9.92, ORGO belongs to the best of the industry, outperforming 94.36% of the companies in the same industry.
ORGO has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.22, ORGO is not doing good in the industry: 68.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 9.92 | ||
| Altman-Z | 2.54 |
ROIC/WACC0.25
WACC8.44%
2.3 Liquidity
A Current Ratio of 2.74 indicates that ORGO has no problem at all paying its short term obligations.
The Current ratio of ORGO (2.74) is worse than 69.06% of its industry peers.
A Quick Ratio of 2.41 indicates that ORGO has no problem at all paying its short term obligations.
The Quick ratio of ORGO (2.41) is worse than 71.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.41 |
3. Growth
3.1 Past
The earnings per share for ORGO have decreased strongly by -63.64% in the last year.
The earnings per share for ORGO have been decreasing by -30.66% on average. This is quite bad
ORGO shows a decrease in Revenue. In the last year, the revenue decreased by -5.63%.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.50% yearly.
EPS 1Y (TTM)-63.64%
EPS 3Y-30.66%
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)-5.63%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Revenue growth Q2Q2.21%
3.2 Future
ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.62% yearly.
The Revenue is expected to grow by 5.85% on average over the next years.
EPS Next Y-133.99%
EPS Next 2Y27.08%
EPS Next 3Y36.62%
EPS Next 5YN/A
Revenue Next Year2.94%
Revenue Next 2Y5.37%
Revenue Next 3Y5.85%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 71.13, which means the current valuation is very expensive for ORGO.
94.36% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (28.53), we can say ORGO is valued expensively.
Based on the Price/Forward Earnings ratio of 44.04, the valuation of ORGO can be described as expensive.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 92.99% of the companies in the same industry.
ORGO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.13 | ||
| Fwd PE | 44.04 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 96.92% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 95.90% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.14 | ||
| EV/EBITDA | 12.61 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 36.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3Y36.62%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGANOGENESIS HOLDINGS INC
NASDAQ:ORGO (5/14/2024, 7:00:02 PM)
Premarket: 2.85 +0 (+0.18%)2.845
-0.11 (-3.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap375.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.13 | ||
| Fwd PE | 44.04 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.27% | ||
| ROE | 2.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 2.91% | ||
| PM (TTM) | 1.34% | ||
| GM | 75.07% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-63.64%
EPS 3Y-30.66%
EPS 5Y
EPS growth Q2Q
EPS Next Y-133.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-5.63%
Revenue growth 3Y8.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y